Cartesian Therapeutics, Inc.
RNACHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Cartesian Therapeutics, Inc. (RNAC) is listed under Biotechnology. The company carries a $187.0M market cap, placing it firmly in the micro-cap category. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Market Cap
$187.0M
Beta
0.72
P/E (TTM)
—
P/E (Fwd)
-1.62
EPS (TTM)
$-5.78
EPS (Fwd)
$-3.81
ROE
—
ROA
-17.4%
Cash
$147.6M
Total Debt
$63.9M
Free CF
-$47.5M
52W Change
-32.5%
Annual Financials
Cash vs Debt
Where RNAC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, RNAC finished 22.35% below its 150-day moving average ($7.83) and 20.94% below its 200-day moving average ($7.69). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RNAC overbought or oversold?
At the October 20, 2026 close, RNAC's RSI(14) was 28.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cartesian Therapeutics, Inc. holds $147.6M in cash against $63.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$47.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has pulled back from $110.8M (2022) to $2.8M (2025), a 97% decline worth watching.
With cash comfortably exceeding debt, RNAC has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cartesian Therapeutics, Inc. and its sector.